Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned.
Hospital-associated transmission
Immunocompromised
Malignancy
Respiratory viruses
SARS CoV-2
Journal
American journal of infection control
ISSN: 1527-3296
Titre abrégé: Am J Infect Control
Pays: United States
ID NLM: 8004854
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
06
06
2022
revised:
19
07
2022
accepted:
20
07
2022
medline:
25
4
2023
pubmed:
29
7
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
The spread of coronavirus disease 2019 (COVID-19) in health care settings endangers patients with cancer. As knowledge of the transmission of COVID-19 emerged, strategies for preventing nosocomial COVID-19 were updated. We describe our early experience with nosocomial respiratory viral infections (RVIs) at a cancer center in the first year of the pandemic (March 2020-March 2021). Nosocomial RVIs were identified through our infection control prospective surveillance program, which conducted epidemiologic investigations of all microbiologically documented RVIs. Data was presented as frequencies and percentages or medians and ranges. A total of 35 of 3944 (0.9%) documented RVIs were determined to have been nosocomial acquired. Majority of RVIs were due to SARS CoV-2 (13/35; 37%) or by rhinovirus/enterovirus (12/35; 34%). A cluster investigation of the first 3 patients with nosocomial COVID-19 determined that transmission most likely occurred from employees to patients. Five patients (38%) required mechanical ventilation and 4 (31%) died during the same hospital encounter. Our investigation of the cluster led to enhancement of our infection control measures. The implications of COVID-19 vaccination on infection control policies is still unclear and further studies are needed to delineate its impact on the transmission of COVID-19 in a hospital setting.
Sections du résumé
BACKGROUND
The spread of coronavirus disease 2019 (COVID-19) in health care settings endangers patients with cancer. As knowledge of the transmission of COVID-19 emerged, strategies for preventing nosocomial COVID-19 were updated. We describe our early experience with nosocomial respiratory viral infections (RVIs) at a cancer center in the first year of the pandemic (March 2020-March 2021).
METHODS
Nosocomial RVIs were identified through our infection control prospective surveillance program, which conducted epidemiologic investigations of all microbiologically documented RVIs. Data was presented as frequencies and percentages or medians and ranges.
RESULTS
A total of 35 of 3944 (0.9%) documented RVIs were determined to have been nosocomial acquired. Majority of RVIs were due to SARS CoV-2 (13/35; 37%) or by rhinovirus/enterovirus (12/35; 34%). A cluster investigation of the first 3 patients with nosocomial COVID-19 determined that transmission most likely occurred from employees to patients. Five patients (38%) required mechanical ventilation and 4 (31%) died during the same hospital encounter.
CONCLUSIONS
Our investigation of the cluster led to enhancement of our infection control measures. The implications of COVID-19 vaccination on infection control policies is still unclear and further studies are needed to delineate its impact on the transmission of COVID-19 in a hospital setting.
Identifiants
pubmed: 35901993
pii: S0196-6553(22)00575-2
doi: 10.1016/j.ajic.2022.07.019
pmc: PMC9310434
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-513Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Med Virol. 2018 Jan;90(1):50-60
pubmed: 28851056
Infect Dis Clin North Am. 2011 Mar;25(1):227-44
pubmed: 21316002
Biol Blood Marrow Transplant. 2020 Nov;26(11):1983-1994
pubmed: 32736007
J Infect Public Health. 2020 Feb;13(2):204-210
pubmed: 31420314
Eur J Med Res. 2020 Aug 12;25(1):32
pubmed: 32787926
Breast Cancer Res Treat. 2020 Jul;182(1):239-242
pubmed: 32405915
MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-1019
pubmed: 34292924
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Environ Res. 2020 Sep;188:109819
pubmed: 32569870
Cancer Lett. 2016 Aug 28;379(1):100-6
pubmed: 27260872
J Clin Microbiol. 2016 Dec 28;55(1):177-182
pubmed: 27795347
Eur J Cancer. 2020 Nov;139:181-187
pubmed: 33035991
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
JAMA Netw Open. 2020 Sep 1;3(9):e2020498
pubmed: 32902653
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1923-30
pubmed: 22210266
Ecancermedicalscience. 2020 May 18;14:1047
pubmed: 32565900
Elife. 2021 Apr 16;10:
pubmed: 33861198
Clin Infect Dis. 2022 May 3;74(9):1579-1585
pubmed: 34329418
Am J Pathol. 2021 Jun;191(6):983-992
pubmed: 33741335
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296675
Clin Infect Dis. 2022 Aug 24;75(1):e296-e299
pubmed: 35137035
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Infect Control Hosp Epidemiol. 2021 Feb;42(2):218-221
pubmed: 32799965
Clin Med (Lond). 2020 Sep;20(5):e141-e145
pubmed: 32788160
Infect Dis Health. 2020 Aug;25(3):175-180
pubmed: 32205064
SN Compr Clin Med. 2020;2(11):2086-2095
pubmed: 32901229
Clin Infect Dis. 2021 Nov 2;73(9):e2829-e2830
pubmed: 33594407
J Hosp Infect. 2020 Oct;106(2):376-384
pubmed: 32702463
Open Forum Infect Dis. 2021 Jun 21;8(8):ofab328
pubmed: 34426792
Ann Transl Med. 2020 May;8(10):629
pubmed: 32566566
Haematologica. 2009 Jun;94(6):833-9
pubmed: 19377073
Front Immunol. 2021 Feb 26;12:631139
pubmed: 33717166
J Natl Cancer Inst. 2021 Jul 1;113(7):820-822
pubmed: 32797188
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Haematologica. 2019 Jul;104(7):1322-1331
pubmed: 31221784
Cancer Lett. 2016 Jan 28;370(2):358-64
pubmed: 26582658